San Francisco startup Construction Therapeutics can be working on an oral, when-daily GLP-one drug named GSBR-1290—the drug surpassed Wall Street’s expectations in June when a mid-stage examine confirmed ordinary weight loss of about six% and it strategies to begin A different mid-st